Business Wire

Oxular Limited Announces Acceptance of IND for Suprachoroidal OXU-001 for the Treatment of Diabetic Macular Edema

Share

Oxular Limited, a clinical-stage ophthalmic company developing long-lasting targeted treatments for retinal disorders to improve patients’ vision, today announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug Application (IND) for suprachoroidal OXU-001 for the treatment of diabetic macular edema (DME). The IND enables advancement of the OXEYE Phase 2 trial, which will evaluate the safety and efficacy of OXU-001 and the potential to provide retinal specialists with a potent, long-lasting, safe, and broad-acting anti-edema and anti-inflammatory treatment for high-prevalence retinal disorders, beginning with DME.

OXU-001 is dexamethasone formulated in a novel biodegradable drug preparation known as Oxuspheres®. OXU-001 will be delivered to the posterior suprachoroidal space of the eye via Oxulumis®, Oxular’s proprietary illuminated microcatheter. This in-office treatment could lead to enhanced efficacy, favorable tolerability, and extended durability to address key unmet needs for people with DME and other retinal disorders.

In 12-month preclinical studies, OXU-001 was well-tolerated and related pharmacokinetic data confirmed that therapeutic drug levels were consistently maintained in target retinal tissues. These data suggest that a single treatment of OXU-001 may provide up to twelve-month treatment effects with an improved clinical safety profile.

“The IND clearance for OXU-001 marks a significant milestone for Oxular,” said Thomas Cavanagh, Chief Executive Officer of Oxular. “DME is the most common and sight-threatening complication of diabetic eye disease and can be debilitating for patients who are often of working age. Today’s treatment approaches have limited durability, requiring frequent anti-VEGF injections into the eye. Also, typically more than two OZURDEX® implants per year may be required. The opportunity to provide patients with a targeted, in-office treatment just once a year could be a game-changer for this prevalent disease. We look forward to advancing OXU-001 into the clinic and evaluating its therapeutic impact in 2023.”

About Oxular

Oxular is a biotechnology company developing long-lasting retinal treatments, delivered suprachoroidally, to improve patients’ vision so they can live better lives. The company has engineered sustained-release drug formulations designed to last up to one year following single dosing and delivery technology to access tissues in the posterior suprachoroidal space via routine, in-office administration. This unique combination aims to substantially improve patients’ vision by increasing therapeutic effectiveness, while reducing side-effects and minimizing the frequency of treatments. Oxular is developing a deep portfolio of product candidates that includes treatments for prevalent retinal diseases, such as diabetic macular edema and diabetic retinopathy. For more information, please visit Oxular.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Monique Allaire
THRUST Strategic Communications
monique@thrustsc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Westfield Completes Acquisition of Lloyd’s of London Syndicate 12003.2.2023 00:18:00 EET | Press release

Westfield today announces the completion of its acquisition of Lloyd’s of London Syndicate 1200 from Argo Group International Holdings Ltd. (NYSE: ARGO). This strategic acquisition establishes Westfield as a global franchise, accelerates Westfield Specialty’sSM growth after a strong first 18 months in the U.S. market, and puts the overall Westfield Specialty portfolio in excess of $1 billion in premium. “This acquisition demonstrates Westfield’s commitment to the international specialty market,” says Westfield President, CEO and Board Chair Ed Largent. “The Lloyd’s of London market offers long-term growth opportunities and we’re excited to offer brokers, agents, and clients greater access to Westfield’s expertise and product offerings.” Westfield brings deep expertise and experience to the international specialty market. Westfield Specialty President Jack Kuhn has a wealth of experience leading global, multi-billion-dollar businesses. Together with Graham Evans, Westfield Specialty Exe

Mobile Commerce Platform Fintiv Partners with Geoswift to Enable Cross-border Digital Remittance in Asia2.2.2023 23:16:00 EET | Press release

Fintiv, a leading mobile commerce platform that brings together payments, loyalty programs, and mobile marketing in one place, has partnered with Geoswift, a payment technology company with significant expertise in Asian cross-border payments, to enable digital remittance payments into Asia through Fintiv’s versatile mobile wallets. The partnership will provide Fintiv’s customers the unique capability of making person-to-person or business-to-business payments into China, India, and many other Asian countries, directly from wallet accounts. With Geoswift’s superior geographical reach through its “GeoRemit” product line, Fintiv’s payment platform can now connect to an extensive number of domestic banks or mobile wallets in Asian countries and territories. For example, payments can be delivered instantly to either the UnionPay debit/credit cards or Alipay wallets of beneficiaries in China. “We are proud to announce a partnership with Geoswift as part of our global digital currency networ

SPIE Announces the Best Products in the Photonics Industry at its 15th Annual Prism Awards2.2.2023 21:22:00 EET | Press release

Yesterday, SPIE, the international society for optics and photonics, recognized the top-rated new optics and photonics products with the industry-focused Prism Awards. The gala evening, held during SPIE Photonics West, also marked the Prism Awards’ 15th anniversary with a champagne toast, a timeline gallery of past winners, and a video showcasing a decade and a half of Prism highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230202005690/en/ The 2023 SPIE Prism Awards: The evening's winners and presenters celebrate their successes and 15 years of photonics innovations. (Photo: Business Wire) Each year, the SPIE Prism Awards reflect the rapidly growing trajectory, exciting latest developments, and rich technical innovations across photonics and photonics-enabled industries. This year, the annual ceremony honored a range of established and emerging companies applying innovative and creative solutions to critical proble

European Authorities Approve Lyophilized S/D Treated Plasma OctaplasLG® for Pre-Hospital Transfusion2.2.2023 18:28:00 EET | Press release

Octapharma AG today announced that European medical authorities have approved the lyophilised presentation of the well-established octaplasLG® - pharmaceutically-licensed S/D treated plasma for transfusion. The line extension, which will be marketed in Europe as a powder and solvent for solution for infusion, offers new and potentially life-saving treatment options in pre-hospital and emergency settings. “The European authorization of octaplasLG® powder continues Octapharma's ongoing commitment to help prevent uncontrolled haemorrhage associated with trauma, which accounts for 30%-50% of all deaths in the first 24 hours"1-5, says Dr. Oliver Hegener, Vice President IBU Critical Care. Trauma results in 4.4 million deaths worldwide annually6, with uncontrolled bleeding being the major cause of potentially preventable death. Trauma-induced coagulopathy (TIC) is an early abnormal response characterised by hypocoagulation, in addition to acute blood loss, shock, hypothermia and metabolic aci

LTIMindtree Partners with Criteo to Drive IT Operational Efficiency2.2.2023 17:00:00 EET | Press release

LTIMindtree, a global technology consulting and digital solutions company, today announced a multi-year engagement that enables Criteo, the commerce media company, to enhance its business agility, IT service quality, and scalability. As part of the engagement, LTIMindtree provides end-to-end IT services to support Criteo’s global operations across all functions. This includes supporting Criteo’s Microsoft Azure Cloud environment, developing a unified data platform, and providing end-user services for its service desk, field, device engineering and Enterprise Service Management. “Enabling Criteo with modern IT systems and capabilities remains a key priority in this fast-moving business environment,” said Beatrice Mabille, VP Internal IT, Criteo. “We look forward to our continued strategic partnership with LTIMindtree.” “We are excited to be a part of Criteo’s business journey as its first-ever strategic IT outsourcing partner,” said Sudhir Chaturvedi, President and Executive Board Membe

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom